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A B S T R A C T
Here we review the literature assessing the roles of the brain dopaminergic and serotonergic systems in the
modulation of pain as revealed by in vivo human studies using positron emission tomography. In healthy
subjects, dopamine D2/D3 receptor availability particularly in the striatum and serotonin 5-HT1A and 5-HT2A
receptor availabilities in the cortex predict the subject's response to tonic experimental pain. High availability of
dopamine D2/D3 or serotonin 5-HT2A receptors is associated with high pain intensity, whereas high availability
of 5-HT1A receptors associates with low pain intensity. Chronic neuropathic pain is associated with high striatal
dopamine D2/D3 receptor availability, for which low endogenous dopamine tone is a plausible explanation,
although a compensatory increase in striatal dopamine D2/D3 receptor density may also contribute. In contrast,
chronic musculoskeletal pain is associated with low baseline availability of striatal dopamine D2/D3 receptors. In
healthy subjects, brain serotonin 5-HT1A as well as dopamine D2/D3 receptor availabilities associate with the
subject's response criterion rather than the capacity to discriminate painful thermal stimuli suggesting that these
neurotransmitter systems act mainly on non-sensory rather than sensory factors of thermally induced pain ex-
perience. Additionally, 5-HT1A receptor availability predicts the subject's discriminative ability but not response
criterion for non-painful tactile test stimuli, while no such correlation is observed with dopamine D2/D3 re-
ceptors. These findings suggest that dopamine acting on striatal dopamine D2/D3 receptors and serotonin acting
on cortical 5-HT1A and 5-HT2A receptors contribute to top-down pain regulation in humans.
1. Introduction
Monoamines dopamine and serotonin exert an important role in the
regulation of several aspects of behavior, such as motivation, re-
inforcement, mood, movement and various cognitive functions.
Positron emission tomography (PET) with selective radioligands for
dopamine and serotonin neurotransmission has allowed in vivo studies
of these neurotransmitter systems in the human brain. This review fo-
cuses on studies assessing the roles of the brain dopamine and serotonin
systems in the pathophysiology and top-down control of pain as re-
vealed by human in vivo PET studies.
2. The brain dopaminergic system
In the brain, two of the dopaminergic cell groups have been shown
to exert significant roles in pain control in humans as well as experi-
mental animals. Of these, substantia nigra pars compacta (also known
as A9) has dopaminergic projections to the dorsal striatum (the pu-
tamen and the caudate nucleus), while the ventral tegmental area (also
known as A10) has dopaminergic projections to the ventral striatum
(including the nucleus accumbens) and the prefrontal cortex. Moreover,
a dopaminergic cell group in the hypothalamus called A11 that pro-
vides dopaminergic innervation of the spinal cord (Tohyama and
Takatsuji, 1998) has been shown to contribute to the dopaminergic
control of spinal pain-relay neurons in experimental animals (e.g.,
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Fleetwood-Walker et al., 1988; Taniguchi et al., 2011). Due to technical
limitations, PET methods have not yet been used for assessing dopa-
minergic pain control under in vivo conditions in the human spinal
cord. Therefore, control of spinal pain-relay neurons is outside the
scope of this review.
Dopamine-induced functions are mediated by G protein-coupled
receptors that are divided into two major groups. The D1 class of do-
pamine receptors consists of D1 and D5 subgroups, while the D2 class of
dopamine receptors consists of D2, D3 and D4 subgroups (Beaulieu and
Gainetdinov, 2011). While at present there is little evidence for the role
of the D1 class of dopamine receptors in pain control, there is abundant
evidence from experimental animal and human studies that the striatal
D2 receptors and the (ventral striatal) D3 receptors have key roles in
mediating dopaminergic pain control in the brain (see for review,
Wood, 2008). Since dopaminergic compounds and the radioligands
used to assess dopamine D2 receptor availability may reflect actions on
the dopamine D3 as well as dopamine D2 receptors, the term dopamine
D2/D3 receptor is used in the present text. Dopamine D2/D3 receptors
are expressed both postsynaptically as heteroreceptors on non-dopa-
minergic target cells and presynaptically as autoreceptors on dopami-
nergic neurons. Dopamine D2/D3 autoreceptors provide a negative
feedback mechanism that reduces the neuronal discharge, synthesis and
release of dopamine as a response to increased extracellular dopamine
level (Beaulieu and Gainetdinov, 2011).
2.1. In vivo measurement of dopamine receptor availability in the human
brain
The development of radioligands binding to dopamine D2/D3 re-
ceptors has allowed studying D2/D3 receptor availability with PET
under in vivo conditions in human subjects (Farde et al., 1988). The
density of dopamine D2/D3 receptors varies markedly between brain
areas innervated by dopaminergic neurons (Hall et al., 1994). In a brain
area with a high density of dopamine D2/D3 receptors, such as the
striatum, e.g. [11C]raclopride has proved useful for PET studies (Hietala
et al., 1994). In extrastriatal brain areas with a considerably lower
density of dopamine D2/D3 receptors, [11C]FLB 457 has been used
successfully in neurotransmitter PET studies (Lundkvist et al., 1998). In
general, differences in neurotransmitter receptor availability for radi-
oligands in PET studies could be explained by a difference in receptor
density, synaptic release or level (tone) of the neurotransmitter, or re-
ceptor affinity. Earlier, it was reported that the dopamine D2/D3 re-
ceptor affinity varies only little suggesting that receptor affinity may be
the least likely factor to explain a change in dopamine D2/D3 receptor
availability (Farde et al., 1995; however, see the effects of dopamine D2
receptor gene polymorphism in chapter 2.5). On the other hand, be-
havioral manipulations or drugs influencing synaptic dopamine levels
have been shown to change dopamine D2/D3 receptor availability
(Laruelle, 2000). Thus, an acute decrease in dopamine D2/D3 receptor
availability for a competing PET ligand can be explained by an in-
creased dopamine neuron burst activity and release of endogenous
dopamine occupying the dopamine receptors. Also potential receptor
internalization can contribute to changes in receptor availability. In
addition to the measurement of dopamine D2/D3 receptor availability,
presynaptic function of dopaminergic neurons in the brain has been
determined in vivo by using 6-[18F]fluorodopa, which reflects the
striatal dopamine synthesis capacity.
In experimental animal studies, activation of striatal dopamine D2/
D3 receptors especially in dorsolateral putamen by intracerebral mi-
croinjection of a selective agonist has attenuated pain-related behavior,
while a dopamine D2/D3 receptor antagonist has enhanced pain beha-
vior in various types of experimental pain conditions (e.g., Ansah et al.,
2007; Magnusson and Fisher, 2000; Taylor et al., 2003). This finding
supports the interpretation that striatal dopamine release is a plausible
explanation for the associations between pain measures and changes in
striatal dopamine D2/D3 receptor availability, particularly when
dealing with treatment-induced effects in challenge-type study designs.
However, differences in receptor availability in baseline conditions may
also be explained by alterations in receptor expression (density) or
combined effects of receptor density and affinity.
2.2. Dopamine D2/D3 receptor availability as a predictor of the response to
pain in healthy subjects
Baseline dopamine D2/D3 receptor availability in the dorsal
striatum of healthy subjects has been reported to have a negative cor-
relation with cold pressor pain (Hagelberg et al., 2002b), heat pain
(Martikainen et al., 2005; Pertovaara et al., 2004) and hypertonic
saline-induced pain (Scott et al., 2006; Wood et al., 2007b): Thus, low
striatal dopamine D2/D3 receptor availability compatible with high
synaptic endogenous dopamine tone predicts low intensity of experi-
mental pain (Table 1). Conditioning pain stimulation produced a con-
tralateral heat pain threshold elevation, the magnitude of which had a
positive correlation with the striatal dopamine D2/D3 receptor avail-
ability in healthy young men (Hagelberg et al., 2002b). In other words,
high availability of dopamine D2/D3 receptors predicts high capacity to
recruit pain inhibitory circuitry that suppresses pain at a distant test
site. In these studies, the findings were lateralized and the lateralization
varied with the investigated parameter (tonic pain intensity versus pain
modulation capacity). Interestingly, a more recent study reported that
heat pain threshold of healthy women had a positive correlation with
striatal dopamine D2/D3 receptor availability (Ledermann et al., 2016).
Among potential factors explaining the difference in the cited striatal
findings has been proposed to be the gender of the studied subjects
(Ledermann et al., 2016). Concerning extrastriatal areas, dopamine D2/
D3 receptor availability in the right medial temporal cortex was nega-
tively correlated with cold pressor tolerance, while cold or heat pain
thresholds were not associated with extrastriatal receptor availability
(Hagelberg et al., 2002b; Pertovaara et al., 2004).
Traditional pain threshold is influenced by the subject's capacity to
discriminate stimuli (a sensory factor in perception) and the subject's
response criterion (a non-sensory factor) determining at which stimulus
intensity the subject rates the stimulus as painful (Clark, 1974). The
sensory and non-sensory factor in the subject's response can be dis-
sociated using an analysis based on the signal detection theory (Swets,
1973). When the sensory and non-sensory factors in the healthy sub-
ject's response to noxious heat were analyzed separately, the capacity to
Table 1
Association of healthy subjects’ somatosensory responses with baseline avail-
ability of striatal dopamine D2/D3 receptors.
Somatosensory response associated with
high dopamine D2/D3 receptor availability
Reference
Intensity of tonic experimental
pain
↑ Hagelberg et al. (2002b), Scott
et al. (2006) and Wood et al.
(2007b)
Capacity to recruit central pain
inhibition
↑ Hagelberg et al. (2002b)
Heat pain threshold ↓ Pertovaara et al. (2004);
Martikainen et al. (2005)
↑ Ledermann et al. (2016)
Capacity to discriminate heat
stimuli
↔ Pertovaara et al. (2004);
Ledermann et al. (2016)
Criterion to classify heat stimuli
painful
↓ Pertovaara et al. (2004);
Ledermann et al. (2016)
Tactile detection threshold ↔ Martikainen et al. (2005)
Capacity to discriminate tactile
stimuli
↔ Martikainen et al. (2005)
Criterion to report detection of
tactile stimuli
↔ Martikainen et al. (2005)
↑, increased; ↓, decreased; ↔, no correlation.
I.K. Martikainen et al. European Journal of Pharmacology 834 (2018) 337–345
338
discriminate heat stimuli failed to have any correlation with the base-
line dopamine D2/D3 receptor availability in striatal or extrastriatal
regions (Ledermann et al., 2016; Pertovaara et al., 2004). However, a
parameter representing the subject's attitude towards pain, the response
criterion, was negatively correlated with the baseline striatal dopamine
D2/D3 receptor availability (Ledermann et al., 2016; Pertovaara et al.,
2004). Accordingly, subjects with high availability of striatal dopamine
D2/D3 receptors, presumably reflecting low extracellular endogenous
dopamine tone, rate the same stimulus as more painful than subjects
with low availability of striatal dopamine D2/D3 receptors. Together,
the studies assessing heat pain sensitivity using the signal detection
theory-based analyses suggest that dorsal striatal dopamine D2/D3 re-
ceptors influence non-sensory rather than sensory factors modulating
the pain response of healthy subjects.
The type or modality of test stimulation may influence the role of
striatal dopamine D2/D3 receptors in modulation of somatic sensations.
Namely, mechanical hyperalgesia induced by an experimental freeze
lesion in healthy subjects was not associated with baseline dopamine
D2/D3 receptor availability in the dorsal striatum (Hagelberg et al.,
2002a, 2004). Nor was the detection threshold, discriminative capacity
or response criterion for innocuous mechanical stimulation correlated
with baseline dopamine D2/D3 receptor availability (Martikainen et al.,
2005).
Intramuscular infusion of hypertonic saline provides a method for
measuring the effect of sustained pain stress. A study assessing the
hypertonic saline-induced change of dopamine D2/D3 receptor avail-
ability in healthy subjects reported that the change of dopamine D2/D3
receptor availability in the dorsal striatum was exclusively correlated
with sensory and affective pain ratings, whereas that in the ventral
striatum was associated with the ratings of negative affect and fear
(Scott et al., 2006). This result implies that dopamine D2/D3 receptor
activation in the dorsal striatum is associated with the sensory and af-
fective pain experience while that in the ventral striatum is associated
with the emotional state in subjects exposed to a sustained pain sti-
mulus.
2.3. Dopamine in placebo analgesia
The role of dopamine in placebo analgesia has been studied in
various experimental paradigms. Baseline dopamine D2/D3 receptor
availability in the dorsal striatum was not associated with the placebo-
induced elevation of heat pain threshold (Martikainen et al., 2005).
However, placebo administration was associated with dopamine release
and dopamine D2/D3 receptor activation in the ventral striatum (Scott
et al., 2007b, 2008). This ventral striatal dopamine system activation
was correlated with expectations of analgesia and with the magnitude
of placebo analgesia as well as the increase in ratings of positive affect.
Further, the nucleus accumbens dopamine D2/D3 receptor activation
was associated with the activation of brain μ-opioid system in regions
involved in pain control. Interestingly, the magnitude of placebo an-
algesia varied considerably among subjects, which, at least partly,
could be explained by individual variability in the ventral striatal do-
paminergic response (Scott et al., 2007b). A more recent PET study
suggested that dopamine might contribute to attenuation of experi-
mental pain by placebo also in the cortex, since dopamine D2/D3 re-
ceptor availability in the ventrolateral prefrontal cortex was lower in
the placebo than control condition (Jarcho et al., 2015).
The role of the dopamine system in placebo analgesia is corrobo-
rated by studies showing the significance of genetic polymorphisms
affecting the dopamine pathway on placebo analgesic response.
Catechol-O-methyltransferase (COMT) val158met polymorphism pre-
dicted placebo analgesia in healthy humans (Yu et al., 2014) and pla-
cebo effect in patients with irritable bowel disease (Hall et al., 2012); in
both studies, COMT val carriers exhibited lower placebo effect than
carriers of the COMT met allele, who have increased dopamine levels in
the prefrontal cortex. A PET imaging study addressed the significance of
a functional single nucleotide polymorphism of the brain derived neu-
rotrophic factor (BDNF) gene val66met on striatal dopamine D2/D3 re-
ceptor activation in the context of placebo (Peciña et al., 2014). In this
study, BDNF met66 carriers had increased baseline dopamine D2/D3
receptor availability suggesting chronically lower dopamine tone. The
BDNF met66 carriers also showed deactivation of dopamine D2/D3 re-
ceptors in the nucleus accumbens during placebo challenge when
compared to BDNF val carriers.
Overall, current evidence indicates an important role for the do-
pamine system and striatal dopamine D2/D3 receptor activation in
placebo analgesia (Peciña and Zubieta, 2015). Despite this, a few stu-
dies have challenged the view that striatal dopamine neurotransmission
would be causally involved in placebo analgesia. Haloperidol, a dopa-
mine D2/D3 receptor antagonist, had no effects on placebo analgesia at
behavioral or neural level, as measured using functional magnetic re-
sonance imaging (Wrobel et al., 2014). In a recent pharmacological
study, haloperidol or levodopa failed to influence placebo effect in
patients with neuropathic pain, although the level of expectancy was
changed (Skyt et al., 2018). Importantly, these studies did not measure
striatal dopamine neurotransmission directly, and it is also not known
whether higher drug doses would have revealed significant placebo
effects.
2.4. Dopamine in the attenuation of pain by repetitive transcranial magnetic
stimulation
Non-invasive repetitive transcranial magnetic stimulation (rTMS) of
the primary motor cortex or prefrontal cortex as well as invasive elec-
tric motor cortex stimulation have been reported to attenuate pain in
experimental and clinical conditions (Maarrawi et al., 2007; Moisset
et al., 2016). There is some evidence suggesting that dopamine might
be among the multiple mechanisms underlying the cortical stimulation-
induced analgesic effect. In an experimental animal model of neuro-
pathy, spinal antinociception induced by motor cortex stimulation was
suppressed following a block of dopamine D2/D3 receptors in the dorsal
striatum or spinal cord, or following local anesthesia of the dopami-
nergic A11 cell group (Viisanen et al., 2012). These findings in an ex-
perimental animal model of neuropathy suggest that dopamine release
contributes to the antinociceptive effect of motor cortex stimulation by
action on dorsal striatal and spinal dopamine D2/D3 receptors. In the
clinic, however, rTMS-induced supraspinal effects on pain appraisal
may be more important for the pain treatment than spinal anti-
nociception (see refs. in Moisset et al., 2016).
In healthy human subjects, dopamine D2/D3 receptor availability
was decreased in the caudate nucleus and the putamen following rTMS
targeting the dorsolateral prefrontal cortex (Strafella et al., 2001) or the
motor cortex (Strafella et al., 2003), respectively. Moreover, rTMS of
the left but not right dorsolateral prefrontal cortex has been shown to
decrease dopamine D2/D3 receptor availability, indicating synaptic
dopamine release, in the anterior cingulate cortex, a brain area im-
plicated (among other functions) in pain (Cho and Strafella, 2009).
These findings are in agreement with the interpretation that rTMS in-
duces dopamine release that causes increased occupation of dopamine
D2/D3 receptors by endogenous dopamine leading to decreased re-
ceptor availability for the radioligand. Interestingly, while rTMS of the
primary motor cortex in humans influenced dopaminergic system in the
dorsal striatum (Strafella et al., 2003), rTMS of the primary motor
cortex in non-human primates reduced dopamine D2/D3 receptor
availability in the ventral rather than dorsal striatum suggesting acti-
vation of meso- rather than nigrostriatal dopamine release (Ohnishi
et al., 2004). Together, these findings are in line with the hypothesis
that dopamine release and its action on the striatal dopamine D2/D3
receptors might contribute to the rTMS-induced behavioral effects,
among which has been reported to be attenuation of pain appraisal,
although not invariably (Moisset et al., 2016). On the other hand, a
recent PET study (Lamusuo et al., 2017), in which expectation and
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thereby potential expectation-induced striatal dopamine release (de la
Fuente-Fernández et al., 2001) was controlled, reported that rTMS of
the primary somatosensory/motor cortex in healthy subjects failed to
produce a significant change in striatal dopamine D2/D3 receptor
availability. However, μ-opioid receptor availability was reduced in-
dicating release of endogenous opioids in various brain areas that are
involved in pain processing (Lamusuo et al., 2017). These findings do
not exclude potential involvement of dopamine and dopamine D2/D3
receptors in the early phase, since the delay from rTMS treatment to
PET scanning in the cited study was close to 2 h (Lamusuo et al., 2017).
This delay is longer than the duration of the phasic dopamine D2/D3
receptor availability change induced by a non-pharmacological ma-
nipulation (Scott et al., 2007a). Considering the existing evidence, it
may thus be hypothesized that an early short-lasting activation of the
dopaminergic system triggers a more prolonged activation of the μ-
opioidergic system (Lamusuo et al., 2017) that contributes to the rTMS-
induced analgesia, similar as has been shown for invasive motor cortex
stimulation (Maarrawi et al., 2007). In line with this proposal, the delay
from the rTMS treatment to PET scanning was significantly shorter
(minutes) in the previous studies demonstrating an rTMS-induced
change of dopamine D2/D3 receptor availability (Strafella et al., 2001,
2003).
2.5. Polymorphism of dopamine D2 receptors influences pain and its
modulation
The finding that polymorphism of the dopamine transporter gene
(DAT-1) is associated with the pain response in healthy humans sup-
ports the concept that dopamine is involved in pain regulation (Treister
et al., 2009). Concerning receptors mediating pain modulation by do-
pamine, genetic variability of dopamine D2 receptors has been shown to
influence receptor availability in PET studies. C957T polymorphism of
the dopamine D2 receptor gene has been associated with striatal do-
pamine D2/D3 receptor availability; in baseline conditions, subjects
with the C957T TT genotype have higher dopamine D2/D3 receptor
availability and accordingly, lower endogenous dopamine tone in the
striatum than those with the CT or CC genotype (Hirvonen et al., 2004,
2009). The C957T polymorphism of the dopamine D2 receptor gene has
also been shown to predict baseline sensitivity to experimental pain and
the magnitude of analgesia induced by rTMS of the primary somato-
sensory cortex in healthy subjects (Jääskeläinen et al., 2014). Subjects
with the TT genotype of the dopamine D2 receptor-coding C957T gene
who presumably have the highest availability of striatal dopamine D2/
D3 receptors (Hirvonen et al., 2004, 2009) had the lowest baseline
thermal pain thresholds and the strongest analgesic effect by rTMS
(Jääskeläinen et al., 2014). Based on this finding, it may be hypothe-
sized that when the proportion of subjects with the C957T TT genotype
is high in the study sample, then striatal dopamine D2/D3 availability
has a strong inverse correlation with baseline pain response and a
strong positive correlation with the capacity to recruit pain inhibition
by various types of conditioning stimulation (such as e.g. in Hagelberg
et al., 2002b). The variation in the magnitude of the rTMS-induced
analgesia with the dopamine D2 receptor C957T polymorphism gives
further support to the proposal that dopamine acting via dopamine D2/
D3 receptors exerts a role in therapeutic pain modulation by rTMS of
the sensory-motor cortex (Jääskeläinen et al., 2014). Interestingly,
val158met polymorphism of COMT, an enzyme involved in dopamine
metabolism only in extrastriatal regions (Yavich et al., 2007), was not
associated with the rTMS-induced increase of thermal pain thresholds
suggesting specific involvement of striatal rather than extrastriatal
dopamine in the rTMS-induced pain modulation (Jääskeläinen et al.,
2014).
2.6. Dopamine in chronic pain conditions that are primarily of neural origin
2.6.1. Burning mouth syndrome and atypical facial pain
Burning mouth syndrome is an orofacial neuropathic pain condition
affecting peripheral and central nervous system (Jääskeläinen, 2018).
Several lines of evidence indicate dopaminergic hypofunction of the
nigrostriatal system in the burning mouth syndrome. This is shown by
the findings that 6-[18F]fluorodopa uptake was reduced (Jääskeläinen
et al., 2001) and dopamine D2/D3 receptor availability increased
(Hagelberg et al., 2003b) in the putamen of burning mouth patients.
These PET findings are similar to those reported in early Parkinson's
disease. Additionally, blink reflex habituation that is controlled by ni-
grostriatal dopamine system (Basso et al., 1993) is frequently deficient
in burning mouth symptom patients (Forssell et al., 2002; Jääskeläinen
et al., 1997). In another chronic orofacial pain condition, atypical facial
pain, dopamine D2/D3 receptor availability in the putamen was in-
creased indicating dopaminergic disorder in the basal ganglia
(Hagelberg et al., 2003a). Unlike in the burning mouth syndrome
(Jääskeläinen et al., 2001), 6-[18F]fluorodopa uptake was not sig-
nificantly decreased in patients with atypical facial pain (Hagelberg
et al., 2003b) suggesting that there may be some differences in the
dopamine-related pathophysiological mechanisms between these two
chronic orofacial pain conditions. Further evidence for the role of do-
pamine in chronic orofacial pain syndromes is the finding that the
prevalence of the C957T TT genotype that is associated with increased
availability of dopamine D2/D3 receptors and low striatal dopamine
tone (Hirvonen et al., 2004, 2009) was significantly higher in patients
with orofacial neuropathic pain than in controls (50% versus 27%;
Jääskeläinen et al., 2014). This is in line with the proposal that the
dopamine system exerts an important role in the pathogenesis of or-
ofacial neuropathic pain (Jääskeläinen, 2012; Jääskeläinen and Woda,
2017).
2.6.2. Central pain in Parkinson's disease
While Parkinson's disease is traditionally considered a movement
disorder, it is accompanied by various cognitive, emotional and sensory
symptoms. Among frequently occurring sensory symptoms in
Parkinson's disease is pain that can be characterized either central
neuropathic or nociceptive type of pain (Conte et al., 2013; Zhu et al.,
2016). It is well established that impairment of the nigrostriatal do-
paminergic system is a pathognomonic finding of the Parkinson's dis-
ease that can be demonstrated under in vivo conditions using PET
(Niccolini et al., 2014). The impaired dopamine system function is ac-
companied by increased striatal availability of dopamine D2/D3 re-
ceptors (Niccolini et al., 2014). This together with the finding that at
least some pain symptoms in Parkinson's disease may be attenuated by
dopaminergic drugs, such as levodopa, suggest that a deficit in the
dopaminergic system is among mechanisms contributing to central pain
in Parkinson's disease (Zhu et al., 2016).
2.6.3. Pain in restless legs syndrome
Restless legs syndrome, as Parkinson's disease, is primarily con-
sidered a movement disorder characterized by unpleasant sensations in
the legs and accompanied by sensory alterations such as pin prick hy-
peralgesia, tactile hypoesthesia and dysesthesia to innocuous cold
(Stiasny-Kolster et al., 2013). PET studies have revealed abnormalities
in the dopaminergic system. For example, dopamine D2/D3 receptor
availability in a sample of restless legs syndrome patients was increased
both in extrastriatal and striatal areas. The most prominent increase
was observed in the ventral striatum (Cervenka et al., 2006). Pre-
synaptic hypofunction of the nigrostriatal dopaminergic system has also
been reported in restless legs patients (Ruottinen et al., 2000). Treat-
ment with L-Dopa significantly alleviated sensory symptoms in the
restless legs syndrome patients supporting the hypothesis that dopa-
minergic impairment may at least partly explain hyperalgesia and
dysesthesia in these patients (Stiasny-Kolster et al., 2013).
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2.6.4. Migraine
DaSilva et al. (2017) studied with PET scanning the potential role of
dopamine in migraine. They found that the baseline striatal dopamine
D2/D3 receptor availability of migraine patients in the interictal phase
(when there is no headache attack) did not differ from that in healthy
controls. During the headache attack, striatal dopamine D2/D3 receptor
availability was significantly higher than in the interictal phase or in
healthy controls. When the trigeminal area of migraine patients was
exposed to experimental heat stimulation-induced challenge that eli-
cited allodynia (unpleasantness) during the migraine attack, dopamine
D2/D3 receptor availability was reduced both in the striatum and the
insula, a cortical structure involved in pain-processing. Experimental
heat-induced challenge reduced dopamine D2/D3 receptor availability
also in healthy controls. These findings suggest that migraine patients
have reduced striatal dopamine release during the headache attack,
which in turn leads to malfunctioning of endogenous pain inhibition.
Still, migraine patients can increase dopamine release during the
headache attack, when confronted with relevant stimulation. Together,
these findings suggest that an imbalance in the dopamine system during
the headache attack may contribute to pain and discomfort in migraine
(DaSilva et al., 2017).
2.7. Dopamine in chronic musculoskeletal pain conditions
2.7.1. Fibromyalgia
Fibromyalgia is a chronic soft tissue pain condition present parti-
cularly in middle-aged women (Russell and Bieber, 2006). In a study
assessing the role of the striatal dopaminergic system in fibromyalgia, it
was found that baseline availability of dopamine D2/D3 receptors in the
ventral as well as dorsal striatum was lower in fibromyalgia patients
than in controls (Wood et al., 2007b). Moreover, the hypertonic saline-
induced decrease of striatal dopamine D2/D3 receptor availability was
reduced in fibromyalgia patients and, unlike in healthy controls, it did
not correlate with the magnitude of hypertonic saline-induced pain
(Wood et al., 2007b). Uptake of 6-[18F]fluorodopa, an index of pre-
synaptic dopaminergic activity, was reduced in the ventral tegmental
area, substantia nigra, thalamus, and anterior cingulate and insular
cortices in fibromyalgia patients (Wood et al., 2007a). This finding
gives support to the proposal that abnormal dopamine system function
contributes to the pathophysiology of fibromyalgia. A more recent
study extended the finding that fibromyalgia is associated with a de-
crease of striatal dopamine D2/D3 receptor availability by showing that
the decrease of receptor availability was significantly stronger in fi-
bromyalgia patients with comorbid depression (Ledermann et al.,
2016). Another recent study further elaborated these findings by
showing that dopamine D2/D3 receptor availability in fibromyalgia
patients was decreased in extrastriatal areas, particularly in brain areas
involved in emotions and stress regulation (Albrecht et al., 2016).
Furthermore, the dopamine D2/D3 receptor availability also in extra-
striatal areas was negatively correlated with the magnitude of ongoing
fibromyalgia pain and with that of pressure-induced experimental pain
(Albrecht et al., 2016). Together, these in vivo PET studies support the
interpretation that abnormal function of the dopaminergic system
contributes to pain in fibromyalgia.
2.7.2. Chronic back pain
In chronic back pain patients, the baseline dopamine D2/D3 receptor
availability and also the tonic experimental pain challenge-induced
dopamine D2/D3 receptor activation, as revealed by the change in do-
pamine D2/D3 receptor availability, were decreased in the right ventral
striatum when compared with healthy controls (Martikainen et al.,
2015). Baseline dopamine D2/D3 receptor availability in the ventral
striatum was positively correlated with baseline availability of μ-opioid
receptors, and negatively with pain challenge-induced μ-opioid re-
ceptor activation in the amygdala. The decreased availability of ventral
striatal dopamine D2/D3 receptors in chronic back pain patients was
associated with high positive affect and low pain sensitivity. This
finding suggests that the changes in the striatal dopaminergic system as
well as those in the amygdaloid opioidergic system may represent
mechanisms helping to cope with chronic pain and accompanying stress
(Martikainen et al., 2015).
2.8. In vivo dopamine findings in pain conditions of neural versus
musculoskeletal origin
Abnormal function of the dopaminergic system has varied with the
type of the chronic pain condition. Pain conditions that are primarily of
neural origin, such as chronic neuropathic orofacial pain (Hagelberg
et al., 2003a, b), migraine in the ictal phase (DaSilva et al., 2017),
central pain in Parkinson's disease (Niccolini et al., 2014), and pain in
restless legs syndrome (Cervenka et al., 2006) have been associated
with an increased baseline availability of striatal dopamine D2/D3 re-
ceptors. In contrast, pain conditions that are primarily of musculoske-
letal origin, such as fibromyalgia (Ledermann et al., 2016; Wood et al.,
2007b) or chronic back pain (Martikainen et al., 2015) associated with
a decreased baseline availability of striatal dopamine D2/D3 receptors.
In chronic pain of primarily musculoskeletal origin, also the capacity to
increase striatal dopamine release is decreased (Martikainen et al.,
2015; Wood et al., 2007b), unlike in migraine (DaSilva et al., 2017).
Presynaptic dopamine level has been reduced independent whether
chronic pain is due to a neural or musculoskeletal disorder, although it
has been only little studied (Table 2).
It remains to be studied whether the increased striatal dopamine
D2/D3 receptor availability in neuropathic pain conditions reflects en-
dogenously low dopamine tone in the striatum or is predominantly due
to compensatory increase in receptor density caused by the reduction in
the endogenous dopaminergic tone. Moreover, it remains to be studied
whether the decreased availability of striatal dopamine D2/D3 receptors
in pain conditions of musculoskeletal origin is related to increased
dopamine release, reduced dopamine D2/D3 receptor density, or both.
Table 2
Striatal dopamine assessed in vivo in clinical pain conditions.
Clinical pain condition DA D2/D3 R availability in baseline Pain challenge-induced DA release Presynaptic DA tone
NEUROPATHIES
Burning mouth ↑ Hagelberg et al. (2003a) ↓ Jääskeläinen et al. (2001)
Atypical facial pain ↑ Hagelberg et al. (2003b) ↔ Hagelberg et al. (2003b)
Migraine (ictal phase) ↑ DaSilva et al. (2017) ↔ DaSilva et al. (2017)
Parkinson's ↑ Niccolini et al. (2014) ↓ Niccolini et al. (2014)
Restless legs ↑ Cervenka et al. (2006) ↓ Ruottinen et al. (2000)
MUSCULOSCELETAL
Fibromyalgia ↓ Wood et al. (2007b); ↓ Wood et al. (2007b); ↓ Wood et al. (2007a)
Ledermann et al. (2016) Ledermann et al. (2016)
Chronic back pain ↓ Martikainen et al. (2015) ↓ Martikainen et al. (2015)
DA, dopamine; R, receptor; ↑, increased; ↓, decreased; ↔, not changed.
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3. The brain serotonergic system
Serotonin pathways in the brain predominantly originate in the
raphe nuclei that are located in the midline from the medulla to the
midbrain. Of these, descending projections of the raphe magnus provide
the main serotonergic innervation of the spinal cord, whereas the
midbrain dorsal raphe nucleus provides ascending serotonergic in-
nervation e.g. to the cerebral cortex (Tohyama and Takatsuji, 1998).
There are multiple types of serotonin receptors that may contribute to
regulation of various aspects of behavior, including pain (Bardin,
2011). There are very few in vivo human PET studies addressing the
role of specific 5-HT receptors in pain. Among the studied 5-HT re-
ceptors is the serotonin 5-HT1A receptor that is implicated in mood
disorders (anxiety, depression), cognition, and modulation of pain
(Lacivita et al., 2012). The G-protein-coupled 5-HT1A receptor is the
predominant autoinhibitory receptor on serotonergic raphe nuclei
(Bjornvatn et al., 1998; Rogawski and Aghajanian, 1981), but it is also
widely distributed as a heteroreceptor in various brain regions in-
nervated by efferent projections of the serotonergic raphe neurons
(Savitz et al., 2009). Another 5-HT receptor type, the role of which in
pain has been studied using PET in humans, is the 5-HT2A receptor that
is also G protein-coupled and involved in the control of mood and
cognition as well as pain (Zhang and Stackman, 2015). Additionally,
the role of serotonin in pain has been studied using PET imaging of
serotonin transporters or synthesis in the human brain.
Experimental animal studies, most of which have focused on the
spinal level that is beyond the focus of this review, have demonstrated
that serotonin has a complex role in the control of pain that may vary
from pro- to antinociception, depending among other things on the type
of 5-HT receptor mediating the response, the neural structure, and the
pathophysiological condition (Millan, 2002). Concerning the brain 5-
HT receptor types studied with PET in human pain control, the 5-HT2A
receptor has been reported to have pronociceptive actions in the spinal
dorsal horn of experimental animals (Millan, 2002), whereas the spinal
5-HT1A receptor has most commonly been reported to promote anti-
nociception (Colpaert, 2006). However, activation of medullary 5-HT1A
autoreceptors has had an opposite effect, reduction of descending ser-
otonergic antinociception (Mico et al., 2006; Wei and Pertovaara,
2006).
3.1. In vivo measurement of 5-HT receptor availability or 5-HT transport
and synthesis
WAY-100635 is a silent antagonist of the 5-HT1A receptor with high
selectivity and affinity (Forster et al., 1995). Its isotope, [carbonyl-11C]
WAY-100635, provides a tool for PET imaging of 5-HT1A receptor
availability in the brain (Pike et al., 1996). [18F]Altanserin has been
used for PET imaging of 5-HT2A receptor availability (Pinborg et al.,
2003), while [11C]3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-
benzonitrile has been used to measure brain serotonin transporter
availability (Kupers et al., 2011) and α-[11C]methyl-L-tryptophan has
been used to study 5-HT synthesis in vivo in the human brain (e.g.,
Sakai et al., 2008).
3.2. The brain serotonin 5-HT1A receptor availability as a predictor of the
response to pain in healthy subjects
So far, there are two studies assessing the association of pain
modulation with the brain 5-HT1A receptor availability in healthy
human subjects (Table 3). The first one of them (Martikainen et al.,
2007) reported that the intensity of cold pressor pain (i.e., the sensory-
discriminative component of pain sensation) was inversely correlated
with the baseline 5-HT1A receptor availability in multiple brain areas.
These included the prefrontal and cingulate cortices, insula, amygdala
and the dorsal raphe nucleus. However, unpleasantness of cold pressor
pain (i.e., the affective-motivational component of pain sensation) was
not correlated with 5-HT1A receptor availability in any of the studied
brain regions. The capacity to recruit pain inhibition by conditioning
noxious peripheral stimulation was positively correlated with the 5-
HT1A receptor availability in the medial prefrontal cortex and amyg-
dala. Furthermore, the magnitude of sympathetic activation induced by
a non-painful Valsalva maneuver was positively correlated with the 5-
HT1A receptor availability in the anterior insula and ventral part of the
anterior cingulate cortex. Together, these results suggest that subjects
with high baseline availability of the brain 5-HT1A receptors rate ex-
perimentally induced pain with low scores and they have high capacity
to recruit central pain inhibition and high capacity to recruit an in-
nocuous sympathetic reflex (Martikainen et al., 2007). Since the ne-
gative correlation of pain intensity with 5-HT1A receptor availability
was observed in multiple brain regions, including also areas that are not
known to be involved in pain processing, it is possible that the corre-
lation reflected some general behavioral effect such as personality traits
and reaction styles (Hirvonen et al., 2015) rather than specific mod-
ulation of pain processing (Martikainen et al., 2007).
The second study on the role of the brain 5-HT1A receptors in pain
control (Martikainen et al., 2009) addressed the question on the spe-
cificity of the correlations described in the first study (Martikainen
et al., 2007). This was done by applying the signal detection theory-
based analysis (Swets, 1973) to assess separately correlations of base-
line receptor availability with the subject's sensory-discriminative ca-
pacity (sensory factor) and response criterion (nonsensory factor) in a
heat pain assay and in a tactile detection assay (Martikainen et al.,
2009). The results indicated that the subject's capacity to discriminate
painful heat stimuli (sensory factor) was not correlated with 5-HT1A
receptor availability in any of the studied brain regions, whereas the
response criterion (nonsensory factor) for heat pain was negatively
correlated with 5-HT1A receptor availability in the dorsal raphe, the
posterior cingulate and orbitofrontal cortices, and the middle temporal
gyrus. In contrast, the response criterion for innocuous touch was not
correlated with 5-HT1A receptor availability in any brain region,
whereas the subject's capacity to discriminate touch was inversely as-
sociated with 5-HT1A receptor availability in the cingulate and medial
prefrontal cortices, and the inferior temporal gyrus (Martikainen et al.,
2009). Together, these results are in line with the hypothesis that the
brain 5-HT1A receptors have a general behavioral effect that influences
attitude towards pain rather than a specific modulatory action on
sensory processing of pain.
The finding that the availability of cortical 5-HT1A receptors cor-
relates with sensory discrimination of touch was unexpected.
Interestingly, it has been shown that navigated transcranial magnetic
stimulation of a fiber tract connecting prefrontal cortex with the pri-
mary somatosensory cortex attenuates the amplitude of touch-evoked
cortical responses (Hannula et al., 2010) and discrimination of tactile
Table 3
Association of healthy subjects’ responses with baseline availability of the brain
serotonin 5-HT1A or 5-HT2A receptors. (Data from selected brain areas; see for
more details in the text).
Response associated with high 5-HT1A receptor
availability
Reference
Intensity of tonic experimental pain ↓ Martikainen et al. (2007)
Capacity to recruit central pain inhibition ↑ Martikainen et al. (2007)
Capacity to recruit innocuous sympathetic
reflex
↑ Martikainen et al. (2007)
Capacity to discriminate heat stimuli ↔ Martikainen et al. (2009)
Criterion to classify heat stimuli painful ↓ Martikainen et al. (2009)
Capacity to discriminate tactile stimuli ↓ Martikainen et al. (2009)
Criterion to report detection of tactile
stimuli
↔ Martikainen et al. (2009)
Response associated with high 5-HT2A receptor availability
Intensity of tonic experimental pain ↑ Kupers et al. (2009)
↑, increased; ↓, decreased; ↔, no correlation.
I.K. Martikainen et al. European Journal of Pharmacology 834 (2018) 337–345
342
stimuli (Gogulski et al., 2015). Thus, it may be speculated that cortical
5-HT1A receptors influenced the function of the fiber tract mediating
the top-down control of the primary somatosensory cortex by the pre-
frontal cortex, and thereby had a selective action on sensory-dis-
criminative processing of tactile signals at cortical level.
Since acute manipulations of the synaptic concentration of en-
dogenous 5-HT have had only a minimal effect on 5-HT1A receptor
availability in humans (Rabiner et al., 2002), the above described re-
ceptor availability results are likely to reflect 5-HT1A receptor density
rather than 5-HT release, although a potential contribution of receptor
affinity may not be excluded.
3.3. The brain serotonin 5-HT2A receptor availability as a predictor of the
response to pain in healthy subjects
The association of brain 5-HT2A receptor availability with pain re-
sponse in healthy subjects has been assessed in one study (Kupers et al.,
2009). The 5-HT2A receptor availability had a positive correlation with
the intensity of pain induced by long- but not short-lasting heat sti-
mulation in primary sensory-motor, posterior cingulate, orbitofrontal
and medial inferior frontal cortices (Table 3). Pain threshold and tol-
erance were not correlated with 5-HT2A receptor availability. Since
tonic heat pain intensity was correlated predominantly with 5-HT2A
receptor availability in brain regions involved in cognitive and affective
functions rather than processing of pain, the authors proposed that the
brain 5-HT2A receptor has a role in cognitive evaluation and emotional
processing of pain (Kupers et al., 2009). The authors also pointed out
that unlike the pre- and postsynaptically located inhibitory 5-HT1A re-
ceptor, the 5HT2A receptor is excitatory and located only post-
synaptically, which possibly explains why the correlation of tonic pain
intensity with 5-HT1A receptor availability was negative (Martikainen
et al., 2007) while that with 5-HT2A receptor availability was positive
(Kupers et al., 2009).
3.4. Serotonin transporter availability in the brain as a predictor of pain
Serotonin transporter is a protein that transports serotonin from the
synaptic cleft back to the presynaptic serotonergic terminal, thereby
terminating the transmission and allowing recycling of the neuro-
transmitter. In healthy subjects, high serotonin transporter availability
in the hypothalamus was associated with low perceived intensity of
tonic heat pain (Kupers et al., 2011). Also heat pain tolerance but not
the intensity of pain induced by brief, phasic stimuli was correlated
with serotonin transporter availability in the hypothalamus (Kupers
et al., 2011). The association of serotonin transporter availability in the
hypothalamus with tonic pain intensity in healthy subjects may reflect
serotonergic modulation of the pain-induced autonomic response and
feedback control by the hypothalamus.
Tominaga et al. (2015) assessed serotonin transporter availability in
patients with functional dyspepsia. They found that serotonin trans-
porter availability was higher in the midbrain and thalamus of func-
tional dyspepsia patients than controls. Moreover, serotonin transporter
availability in the midbrain and thalamus correlated with abdominal
pain in the patients. Together these findings suggest that serotonin in
the midbrain and the thalamus exerts a role in abdominal symptoms,
including pain of functional dyspepsia patients.
3.5. Brain serotonin synthesis in painful clinical conditions
In vivo PET imaging of brain serotonin synthesis indicated increased
synthesis widely in the brain during an acute migraine attack.
Treatment with sumatriptan, a 5-HT1 receptor agonist, promptly de-
creased brain serotonin synthesis and this was accompanied by at-
tenuation of migraine pain (Sakai et al., 2008). Brain serotonin synth-
esis was lowest in the interictal phase. These findings suggest that
abnormality in serotonin synthesis has a role in the pathogenesis of
migraine and that an effective treatment of migraine attack may be
based on negative feedback regulation of serotonin synthesis by a 5-HT1
receptor agonist.
In female patients with irritable bowel syndrome serotonin synth-
esis in the right medial temporal gyrus was greater than in healthy
controls suggesting that brain serotonin synthesis may also be related to
visceral pain processing (Nakai et al., 2003). However, in male patients
no such difference was found.
4. Conclusions
The results of in vivo brain imaging studies cited in the present
review suggest that dopamine acting on dopamine D2/D3 receptors and
serotonin acting on 5-HT1A and 5-HT2A receptors contribute to mod-
ulation of pain. These modulatory effects, however, may reflect action
on non-sensory mechanisms, such as attention and gating of painful
stimuli as well as subjective attitude towards pain, rather than a se-
lective action on sensory-discriminative processing of pain signals.
Looped circuitries connecting the cortex and the striatum are in-
volved in assessing competing priorities when choosing the appropriate
behavioral response and tone when exposed to various environmental
challenges (McHaffie et al., 2005). Concerning the cited human studies
on striatal dopamine D2/D3 receptors and cortical serotonin receptors,
it would be interesting to know whether these neurotransmitter systems
contribute to pain regulation independent of each other or whether
they have a coordinated interaction in the corticostriatal circuitry. In
vivo imaging of these different receptors in the same subjects would
allow determining whether e.g. an increased intensity of tonic experi-
mental pain is associated with high availability of striatal dopamine D2/
D3 receptors, low availability of cortical 5-HT1A receptors and high
availability of cortical 5-HT2A receptors, as expected if they act in
concert in the corticostriatal circuitry (Hagelberg et al., 2002b; Kupers
et al., 2009; Martikainen et al., 2007). Modulation of pain by the do-
paminergic or serotonergic pathways or their interaction in man is also
an interesting area for drug development aiming at an improved
pharmacological treatment of pain.
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